Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Novel Transcription Factor-Driven Approach for Mural Progenitor Cells Generation

Award Number: R01HL172968
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/07/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

A Novel Transcription Factor-Driven Approach for Mural Progenitor Cells Generation - PROJECT SUMMARY/ABSTRACT Mural cells, including pericytes and smooth muscle cells, are critical for vascular development, function, and stability. Dysregulation of mural cells can lead to vascular abnormalities, emphasizing the need for generating functional mural cells to explore novel therapeutic approaches in vascular disorders, tissue repair, and regenerative medicine. Human induced pluripotent stem cells (iPSCs) offer a promising method for obtaining patient-specific mural cells; however, conventional chemical-based differentiation methods are limited in scope and precision. Inducible transcription factors (TFs) have gained traction as a differentiation strategy, offering precise temporal control and the potential for simultaneous differentiation of multiple cell types. However, identifying TFs for mural cell differentiation remains challenging. Our overarching goal is to develop TF-driven strategies for the effective differentiation of human iPSCs into competent vascular cells for regenerative medicine. Our group previously demonstrated the successful generation of vascular endothelial cells (iECs) from iPSCs using ETV2, a pioneer TF. More recently, we identified that another TF, NK3 Homeobox 1 (NKX3.1), facilitates the generation of mural progenitor cells (iMPCs) from iPSCs. These iMPCs display crucial mural cell characteristics and mature into fully differentiated mural cells upon interaction with ECs. Our group has also developed a novel vascular organoid (VO) model that allows concurrent co-differentiation of iPSCs into iECs and iMPCs and facilitates the maturation of iMPCs. Our central hypothesis is that NKX3.1 dictates mural cell lineage fate, and its activation can effectively generate iMPCs, introducing a novel method for creating an unlimited supply of functional mural cells for regenerative medicine. To test these hypotheses and elucidate the mechanisms underlying NKX3.1-driven mural cell differentiation and maturation, we propose three specific aims. In Aim-1, we seek to elucidate the transcriptional regulation of iMPC specification using NKX3.1. Aim-2 delves into the mechanisms of mural cell maturation in the VO model, examining how EC interactions affect iMPC maturation. In Aim-3, we seek to evaluate the therapeutic potential of iMPCs in ischemic tissues, determining whether iMPCs can act as a source of functional perivascular cells in vivo, supporting EC engraftment and contributing to the stability of newly generated blood vessels. We anticipate that these investigations will uncover the molecular underpinnings of mural cell lineage determination and functionality, ultimately advancing our understanding of mural cell development and therapeutic potential. This knowledge will pave the way for patient- specific strategies for treating vascular disorders and advancing vascular regenerative medicine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $638,118 )
2025	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Blood Diseases and Resources Research	001	2	6/26/2025	NON-COMPETING CONTINUATION	$63,812
2025	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Blood Diseases and Resources Research	000	2	4/10/2025	NON-COMPETING CONTINUATION	$574,306
														Subtotal = $638,118

Issue Date FY: 2024 ( Subtotal = $638,118 )
2024	2024	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Blood Diseases and Resources Research	001	1	6/28/2024	NEW	$63,812
2024	2024	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Blood Diseases and Resources Research	000	1	5/7/2024	NEW	$574,306
														Subtotal = $638,118

Grand Total All Awards = $1,276,236

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Novel Transcription Factor-Driven Approach for Mural Progenitor Cells Generation

Award Number: R01HL172968

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/07/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer